ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

CD

CHU de Besançon at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

CHU de Besançon takes part in 4 sessions at ESMO 2026 in Madrid. Its work spans breast and digestive cancers, with studies of biomarkers and treatment outcomes, alongside early melanoma. One study assesses markers that may help predict benefit from chemotherapy after pancreatic cancer surgery.

OrganizationESMO 2026 Attendance
CD
CHU de Besançon
Besançon, France
Cancer centre & hospital
Regional university hospital in Besançon, eastern France.
Poster
Sat Oct 24
12:00–12:45
Beyond clinical risk: Real-world insights from genomic profiling in early breast cancer – the FREDO-ODX study
Saturday Poster Display session 1
Breast cancerBiomarkers & precision oncology
Poster
Sun Oct 25
12:00–12:45
Chair
Sun Oct 25
14:45–16:00
More cures in early melanoma
with Maria Sklodowska-Curie National Research Institute of Oncology
Melanoma & skin cancers
Talk
Sun Oct 25
14:45–14:50
Presentation of case/condition
More cures in early melanoma
Melanoma & skin cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at CHU de Besançon

Tell us what you sell and we’ll find the people at CHU de Besançon most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction